Katalin Sandor

Katalin Sandor

Auto-generated profile, based on publicly available information

Katalin Sandor

Department of Physiology and Pharmacology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AGAndreas Goebel
Andreas Goebel
EKEmerson Krock
Emerson Krock
CGClive Gentry
Clive Gentry
MIMathilde Israel
Mathilde Israel
AJAlexandra Jurczak
Alexandra Jurczak
DADavid Andersson
David Andersson
Fibromyalgia syndrome (FMS) is characterized by widespread pain and tenderness, and patients typically experience fatigue and emotional distress. The etiology and pathophysiology of fibromyalgia are not fully explained and there are no effective drug treatments. Here we show that IgG from FMS patients produced sensory hypersensitivity by sensitizing nociceptive neurons. Mice treated with IgG from FMS patients displayed increased sensitivity to noxious mechanical and cold stimulation, and nociceptive fibers in skin-nerve preparations from mice treated with FMS IgG displayed an increased responsiveness to cold and mechanical stimulation. These mice also displayed reduced locomotor activity, reduced paw grip strength, and a loss of intraepidermal innervation. In contrast, transfer of IgG-depleted serum from FMS patients or IgG from healthy control subjects had no effect. Patient IgG did not activate naive sensory neurons directly. IgG from FMS patients labeled satellite glial cells and neurons in vivo and in vitro, as well as myelinated fiber tracts and a small number of macrophages and endothelial cells in mouse dorsal root ganglia (DRG), but no cells in the spinal cord. Furthermore, FMS IgG bound to human DRG. Our results demonstrate that IgG from FMS patients produces painful sensory hypersensitivities by sensitizing peripheral nociceptive afferents and suggest that therapies reducing patient IgG titers may be effective for fibromyalgia.

13 June 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AFAlex Bersellini Farinotti
Alex Bersellini Farinotti
GWGustaf Wigerblad
Gustaf Wigerblad
DNDiana Nascimento
Diana Nascimento
DBDuygu B. Bas
Duygu B. Bas
CUCarlos Morado Urbina
Carlos Morado Urbina
CSCamilla I. Svensson
Camilla I. Svensson
Rheumatoid arthritis–associated joint pain is frequently observed independent of disease activity, suggesting unidentified pain mechanisms. We demonstrate that antibodies binding to cartilage, specific for collagen type II (CII) or cartilage oligomeric matrix protein (COMP), elicit mechanical hypersensitivity in mice, uncoupled from visual, histological and molecular indications of inflammation. Cartilage antibody–induced pain-like behavior does not depend on complement activation or joint inflammation, but instead on tissue antigen recognition and local immune complex (IC) formation. smFISH and IHC suggest that neuronal Fcgr1 and Fcgr2b mRNA are transported to peripheral ends of primary afferents. CII-ICs directly activate cultured WT but not FcRγ chain–deficient DRG neurons. In line with this observation, CII-IC does not induce mechanical hypersensitivity in FcRγ chain–deficient mice. Furthermore, injection of CII antibodies does not generate pain-like behavior in FcRγ chain–deficient mice or mice lacking activating FcγRs in neurons. In summary, this study defines functional coupling between autoantibodies and pain transmission that may facilitate the development of new disease-relevant pain therapeutics.

8 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YHYibo He
Yibo He
CGChangrong Ge
Changrong Ge
ÀMÀlex Moreno-Giró
Àlex Moreno-Giró
BXBingze Xu
Bingze Xu
CBChristian Michel Beusch
Christian Michel Beusch
Rikard HolmdahlRikard Holmdahl
Rikard Holmdahl
Although elevated levels of anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis (RA), the in vivo functions of these antibodies remain unclear. Here, we have expressed monoclonal ACPAs derived from patients with RA, and analyzed their functions in mice, as well as their specificities. None of the ACPAs showed arthritogenicity nor induced pain-associated behavior in mice. However, one of the antibodies, clone E4, protected mice from antibody-induced arthritis. E4 showed a binding pattern restricted to skin, macrophages and dendritic cells in lymphoid tissue, and cartilage derived from mouse and human arthritic joints. Proteomic analysis confirmed that E4 strongly binds to macrophages and certain RA synovial fluid proteins such as α-enolase. The protective effect of E4 was epitope-specific and dependent on the interaction between E4-citrullinated α-enolase immune complexes with FCGR2B on macrophages, resulting in increased IL-10 secretion and reduced osteoclastogenesis. These findings suggest that a subset of ACPAs have therapeutic potential in RA.

20 December 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
HLHarald Lund
Harald Lund
MHMatthew A. Hunt
Matthew A. Hunt
ZKZerina Kurtović
Zerina Kurtović
KSKatalin Sandor
Katalin Sandor
PKPaul B. Kägy
Paul B. Kägy
CSCamilla I. Svensson
Camilla I. Svensson
In dorsal root ganglia (DRG), macrophages reside close to sensory neurons and have largely been explored in the context of pain, nerve injury, and repair. However, we discovered that most DRG macrophages interact with and monitor the vasculature by sampling macromolecules from the blood. Characterization of the DRG vasculature revealed a specialized endothelial bed that transformed in molecular, structural, and permeability properties along the arteriovenous axis and was covered by macrophage-interacting pericytes and fibroblasts. Macrophage phagocytosis spatially aligned with peak endothelial permeability, a process regulated by enhanced caveolar transcytosis in endothelial cells. Profiling the DRG immune landscape revealed two subsets of perivascular macrophages with distinct transcriptome, turnover, and function. CD163+ macrophages self-maintained locally, specifically participated in vasculature monitoring, displayed distinct responses during peripheral inflammation, and were conserved in mouse and man. Our work provides a molecular explanation for the permeability of the blood–DRG barrier and identifies an unappreciated role of macrophages as integral components of the DRG-neurovascular unit.

19 November 2021 in Pain
Verified
Journal Article
Open access
AJAlexandra Jurczak
Alexandra Jurczak
LDLauriane Delay
Lauriane Delay
JBJulie Barbier
Julie Barbier
NSNils Simon
Nils Simon
EKEmerson Krock
Emerson Krock
CSCamilla I. Svensson
Camilla I. Svensson
Several bone conditions e.g., bone cancer, osteoporosis and rheumatoid arthritis (RA) are associated with a risk of developing persistent pain. Increased osteoclast activity is often the hallmark of these bony pathologies and leads not only to bone remodeling but is also a source of pronociceptive factors that sensitize the bone-innervating nociceptors. Although historically bone loss in RA has been thought to be a consequence of inflammation, both bone erosion and pain can occur years before the symptom onset. Here we have addressed the disconnection between inflammation, pain and bone erosion by using a combination of two monoclonal antibodies isolated from B-cells of RA patients. We have found that mice injected with B02/B09 mAbs developed a long-lasting mechanical hypersensitivity which was accompanied by bone erosion in the absence of joint edema or synovitis. Intriguingly, we have noted a lack of analgesic effect of naproxen and a moderate elevation of few inflammatory factors in the ankle joints suggesting that B02/B09-induced pain-like behavior does not depend on inflammatory processes. In contrast, we found that inhibiting osteoclast activity and ASIC3 signaling prevented the development of B02/B09-mediated mechanical hypersensitivity. Moreover, we have identified phospholipase A2 (sPLA2) and lysophospatidylcholine 16:0 as critical components of B02/B09-induced pain-like behavior and shown that treatment with sPLA2 inhibitor reversed B02/B09-induced mechanical hypersensitivity and bone erosion. Taken together, our study suggests a potential link between bone erosion and pain in a state of subclinical inflammation and offers a step forward in understanding the mechanisms of bone pain in diseases like RA.

2 May 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
MSMaarten M. Steinz
Maarten M. Steinz
MPMalin Persson
Malin Persson
BABejan Aresh
Bejan Aresh
KOKarl Olsson
Karl Olsson
ACArthur J. Cheng
Arthur J. Cheng
JLJohanna T. Lanner
Johanna T. Lanner
Skeletal muscle weakness in patients suffering from rheumatoid arthritis (RA) adds to their impaired working abilities and reduced quality of life. However, little molecular insight is available on muscle weakness associated with RA. Oxidative stress has been implicated in the disease pathogenesis of RA. Here, we show that oxidative posttranslational modifications of the contractile machinery targeted to actin result in impaired actin polymerization and reduced force production. Using mass spectrometry, we identified the actin residues targeted by oxidative 3-nitrotyrosine (3-NT) or malondialdehyde (MDA) adduct modifications in weakened skeletal muscle from mice with arthritis and patients afflicted by RA. The residues were primarily located in 3 distinct regions positioned at matching surface areas of the skeletal muscle actin molecule from arthritic mice and patients with RA. Moreover, molecular dynamics simulations revealed that these areas, here coined “hotspots,” are important for the stability of the actin molecule and its capacity to generate filaments and interact with myosin. Together, these data demonstrate how oxidative modifications on actin promote muscle weakness in RA patients and may provide novel leads for targeted therapeutic treatment to improve muscle function.